Eurand Chief Financial Officer to Step Down in Early 2011

Eurand Chief Financial Officer to Step Down in Early 2011

AMSTERDAM, THE NETHERLANDS, Sep 10, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the resignation of its Chief Financial Officer, Mario Crovetto, effective January 2011.

"The Board and I wish to express our gratitude to Mario for his many contributions and service to Eurand over the years and wish him well in his future endeavors," said Gearoid Faherty, Chairman and Chief Executive Officer.

"I've been fortunate to spend 11 exciting and rewarding years at a great company like Eurand, and I will miss it," Crovetto stated.

Eurand will begin a search for a new CFO immediately.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.

Contacts:

Bill Newbould
Vice President
Investor Relations
Eurand N.V.
+1 267-759-9335
Email Contact

Nick Laudico/Sara Pellegrino
The Ruth Group
+1 646-536-7030/7002
Email Contact
Email Contact


SOURCE: Eurand N.V.

http://www2.marketwire.com/mw/emailprcntct?id=040130E320B21ECD
http://www2.marketwire.com/mw/emailprcntct?id=328E74A281AC2F91
http://www2.marketwire.com/mw/emailprcntct?id=F632DBB10FC5CDCC

Copyright 2010 Marketwire, Inc., All rights reserved.

News Provided by COMTEX

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.